Or have the UK’s accusations of French vaccine nationalism been wide of the mark? After all, it’s not a race, and if Europeans chose to be careful over the AstraZeneca vaccine because they felt there was a lack of clinical evidence for the over-65s, that would hardly be the first time the EU’s precautionary principle has slowed things down.
Coronavirus: What’s behind France’s AstraZeneca turnaround?
